Skip to main content

Table 2 Anti-tumor effect of nivolumab in previously treated malignant pleural mesothelioma patients

From: Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma

No. of patients

11

 

Best overall response (%)

 CR

0

(0.0)

 PR

2

(18.2)

 SD

8

(72.7)

 PD

1

(9.1)

ORR

18.2%

 

DCR

90.9%

 
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease control rate